Skip to main content

Drug Interactions between Seromycin and TheraCys

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

cycloSERINE BCG

Applies to: Seromycin (cycloserine) and TheraCys (bcg)

CONTRAINDICATED: Antituberculosis drugs may interfere with the anti-tumor activity of intravesical BCG, which contains a live, attenuated strain of Mycobacterium bovis. Available data suggest that intravesical BCG may be sensitive to most antibiotics, particularly those that are routinely used in the treatment of tuberculosis such as streptomycin, para-aminosalicylic acid (PAS), isoniazid (INH), rifampin, and ethambutol. It is reportedly not sensitive to pyrazinamide or cycloserine. Regardless of clinical susceptibility data, however, most antibacterials may still interfere with BCG in the bladder due to their high urinary recovery.

MANAGEMENT: Concomitant use of antituberculosis drugs is considered contraindicated during intravesical BCG therapy. Moreover, intravesical BCG should not be used in patients with active tuberculosis. If persistent fever develops or an acute febrile illness consistent with BCG infection occurs during intravesical BCG therapy, the medication should be permanently discontinued and the patient immediately evaluated and treated for BCG infection. An infectious disease consultation should be sought in determining the appropriate treatment. There are no data to suggest that the acute, local urinary tract toxicity common with intravesical administration of BCG is due to mycobacterial infection, thus antituberculosis drugs should not be used to prevent or treat the local, irritative toxicities of intravesical BCG.

References

  1. "Product Information. Tice BCG Live (for intravesical use) (BCG)." Organon
  2. Durek C, Rusch-Gerdes S, Jocham D, Bohle A (1999) "Interference of modern antibacterials with bacillus Calmette-Guerin viability." J Urol, 162, p. 1959-62
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  4. Cerner Multum, Inc. "Australian Product Information."
  5. "Product Information. Tice BCG Live (for intravesical use) (BCG)." Organon Pharmaceuticals
View all 5 references

Switch to consumer interaction data

Drug and food interactions

Major

cycloSERINE food

Applies to: Seromycin (cycloserine)

GENERALLY AVOID: Coadministration with alcohol may potentiate some of the central nervous system adverse effects of cycloserine and its prodrug, terizidone. These effects may include dizziness, drowsiness, depression, anxiety, psychoses, memory impairment, confusion, and convulsions.

MANAGEMENT: Patients should be advised to avoid the consumption of alcohol during treatment with cycloserine or terizidone. The use of these medications is contraindicated in patients with chronic alcohol consumption or alcoholism.

MONITOR CLOSELY: Coadministration with caffeine may potentiate some of the central nervous system adverse effects of cycloserine and its prodrug, terizidone. These effects may include insomnia, excitability, irritability, anxiety, tremor, psychoses, and convulsions.

MANAGEMENT: Caution is advised when cycloserine or terizidone is used with caffeine. Consumption of certain beverages or stimulants with very high caffeine levels should be avoided as a precautionary measure.

References

  1. (2001) "Product Information. Seromycin (cycloserine)." Dura Pharmaceuticals
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer